. Author manuscript; available in PMC: 2013 Feb 1.

Published in final edited form as: Depress Anxiety. 2012 Feb;29(2):111–122. doi: 10.1002/da.20918

Table 1.

Medication dosage guidelines and blinded conditions.

Week of Treatment	Open Label	Single Blind
Escitalopram + Placebo

	Escitalopram	Placebo^a
Baseline	10 mg/d
Week 2		1 tablet/d
Week 4	20 mg/d^b	2 tablets/d

Bupropion-SR + Escitalopram

	Bupropion-SR	Escitalopram^a
Baseline	150 mg/d
Week 1	300 mg/d
Week 2		10 mg/d
Week 4	400 mg/d^b	20 mg/d^b
Week 6+	400 mg/d^b	20 mg/d^b

Venlafaxine-XR + Mirtazapine

	Venlafaxine-XR	Mirtazapine^a
Baseline	37.5 mg/d
Day 4	75 mg/d
Week 1	150 mg/d
Week 2		15 mg/d
Week 4	225 mg/d	30 mg/d
Week 6		45 mg/d^b
Week 8	300 mg/d^b

Note: all medication increases were on the conditions that QIDS-C₁₆ >5 and side effects were tolerable.

Participant blinded to this medication throughout the 7-month study. Research coordinators and physicians were not blinded to any medication to maximize safety and facilitate informed flexible dosing decisions.

Maximum dose (bupropion SR was in divided dose).